Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Benztropine Mesylate 1 Mg Tabs 1000 By Upsher-Smith Labs.

Image 0 of Benztropine Mesylate 1 Mg Tabs 1000 By Upsher-Smith Labs.Image 1 of Benztropine Mesylate 1 Mg Tabs 1000 By Upsher-Smith Labs.

Benztropine Mesylate 1 Mg Tabs 1000 By Upsher-Smith Labs.

Call for Price

Benztropine Mesylate 1 Mg Tabs 1000 By Upsher-Smith Labs. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD2625887/RXB10004568
Size : 1000
Selling UoM : EA
NDC: 00832-1081-10
UPC Barcode : 308321081105
Supplier: 0050000784 UPSHER-SMITH LABS INC
Supplier Material : 108110
Generic Code : 004590 BENZTROPINE MESYLATE ORAL TABLET 1 MG
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : GRX Gene

Have a question?

  Call for Price

Product Description.:

832 BM1
tablet , white , scored , oval oblong

Benztropine mesylate is a synthetic compound containing structural features found in atropine and diphenhydramine.

Each tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg of benztropine mesylate. Each tablet contains the following inactive ingredients: magnesium stearate, microcrystalline cellulose, povidone and pregelatinized starch.

WARNINGS: Safe use in pregnancy has not been established.

Benztropine mesylate may impair mental and/or physical abilities required for performance of hazardous tasks such as operating machinery or driving a motor vehicle.

When benztropine is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly. Paralytic ileus, hyperthermia and heat stroke, all of which have sometimes been fatal, have occurred in patients taking anticholinergic-type antiparkinsonism drugs, including benztropine in combination with phenothiazines and/or tricyclic antidepressants.

Since benztropine contains structural features of atropine, it may produce anhidrosis. For this reason, it should be administered with caution during hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, the alcoholic, those who have central nervous system disease, and those who do manual labor in a hot environment. Anhidrosis may occur more readily when some disturbance of sweating already exists. If there is evidence of anhidrosis, the possibility of hyperthermia should be considered. Dosage should be decreased at the discretion of the physician so that the ability to maintain body heat equilibrium by perspiration is not impaired. Severe anhidrosis and fatal hyperthermia have occurred.

PRECAUTIONS:

General
Since benztropine mesylate has cumulative action, continued supervision is advisable. Patients with a tendency to tachycardia and patients with prostatic hypertrophy should be observed closely during treatment.

Dysuria may occur, but rarely becomes a problem. Urinary retention has been reported with benztropine.

The drug may cause complaints of weakness and inability to move particular muscle groups, especially in large doses. For example, if the neck has been rigid and suddenly relaxes, it may feel weak, causing some concern. In this event dosage adjustment is required.

Mental confusion and excitement may occur with large doses, or in susceptible patients. Visual hallucinations have been reported occasionally. Furthermore, in the treatment of extrapyramidal disorders due to neuroleptic drugs (e.g., phenothiazines) in patients with mental disorders, occasionally there may be intensification of mental symptoms. In such cases, antiparkinsonian drugs can precipitate a toxic psychosis. Patients with mental disorders should be kept under careful observation, especially at the beginning of treatment or if dosage is increased.

Tardive dyskinesia may appear in some patients on long-term therapy with phenothiazines and related agents or may occur after therapy with these drugs has been discontinued. Antiparkinsonism agents do not alleviate the symptoms of tardive dyskinesia, and in some instances may aggravate them. Benztropine is not recommended for use in patients with tardive dyskinesia.

The physician should be aware of the possible occurrence of glaucoma. Although the drug does not appear to have any adverse effect on simple glaucoma, it probably should not be used in angle-closure glaucoma.

Drug Interactions
Antipsychotic drugs such as phenothiazines or haloperidol tricyclic antidepressants